Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells.
By J. Dannull, Z. Su, D. Rizzieri, Benjamin K. Yang, Doris Coleman, Donna R. Yancey, A. Zhang, P. Dahm, N. Chao, Eli Gilboa and 1 more. Journal of Clinical Investigation, 2005
1,029 citations recorded by the source corpus.
Subfields: Immunology, Oncology
View Paper: https://www.semanticscholar.org/paper/034897a87f9c0609995b745c8de0d0d0894094cf
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Immunology
- N. Restifo
- S. Rosenberg
- L. Gattinoni
- H. Nishikawa
- D. Powell
- Shimon Sakaguchi
- W. Zou
- Alexander Y. Rudensky
In Oncology
Citations in the corpus
- Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans (2013, result): “Some clinical studies have shown the potential of depleting CD25-expressing lymphocytes to augment antitumor immune responses (12, 13); yet other similar studies failed to support the effects (10, 14, 15).”
- Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. (2007, background): “Therefore, a combination of depletion or attenuation of Tregs and concomitant stimulation of tumor-specific effector T cells, systemically or locally in tumors, may be a feasible immunotherapy for HCC; such as combination has been proved to be effective in some other cancer types.(32,33) Notably, ev”
- Adoptive immunotherapy for cancer: building on success (2006, background): “For example, T Reg cells and other immunosuppressive cells might be selectively depleted with directed immunotoxins or suppressed by administering a cytokine such as TN”